Switch theme
Sign up to access all valuation multiples
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.
2001
63
LTM Revenue $16.0M
LTM EBITDA $2.6M
$64.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gentian Diagnostics has a last 12-month revenue of $16.0M and a last 12-month EBITDA of $2.6M.
In the most recent fiscal year, Gentian Diagnostics achieved revenue of $14.4M and an EBITDA of $2.8M.
Gentian Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gentian Diagnostics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $12.9M | $14.4M | XXX | XXX | XXX |
| Gross Profit | $4.6M | $6.6M | XXX | XXX | XXX |
| Gross Margin | 36% | 46% | XXX | XXX | XXX |
| EBITDA | -$0K | $2.8M | XXX | XXX | XXX |
| EBITDA Margin | 0% | 20% | XXX | XXX | XXX |
| Net Profit | -$2.2M | -$1.0M | XXX | XXX | XXX |
| Net Margin | -17% | -7% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Gentian Diagnostics's stock price is NOK 49 (or $5).
Gentian Diagnostics has current market cap of NOK 756M (or $71.4M), and EV of NOK 681M (or $64.4M).
See Gentian Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $64.4M | $71.4M | XXX | XXX | XXX | XXX | $0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Gentian Diagnostics has market cap of $71.4M and EV of $64.4M.
Gentian Diagnostics's trades at 4.0x LTM EV/Revenue multiple, and 24.7x LTM EBITDA.
Analysts estimate Gentian Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Gentian Diagnostics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $64.4M | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | 22.9x | XXX | XXX | XXX |
| P/E | 16.7x | XXX | XXX | XXX |
| P/E/Growth | -2.4x | XXX | XXX | XXX |
| EV/FCF | 271.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGentian Diagnostics's NTM/LTM revenue growth is 29%
Gentian Diagnostics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Gentian Diagnostics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Gentian Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Gentian Diagnostics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -593780% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 48% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 44% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gentian Diagnostics acquired XXX companies to date.
Last acquisition by Gentian Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Gentian Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Gentian Diagnostics founded? | Gentian Diagnostics was founded in 2001. |
| Where is Gentian Diagnostics headquartered? | Gentian Diagnostics is headquartered in Norway. |
| How many employees does Gentian Diagnostics have? | As of today, Gentian Diagnostics has 63 employees. |
| Who is the CEO of Gentian Diagnostics? | Gentian Diagnostics's CEO is Ms. Hilja Ibert. |
| Is Gentian Diagnostics publicy listed? | Yes, Gentian Diagnostics is a public company listed on OSL. |
| What is the stock symbol of Gentian Diagnostics? | Gentian Diagnostics trades under GENT ticker. |
| When did Gentian Diagnostics go public? | Gentian Diagnostics went public in 2016. |
| Who are competitors of Gentian Diagnostics? | Similar companies to Gentian Diagnostics include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Gentian Diagnostics? | Gentian Diagnostics's current market cap is $71.4M |
| What is the current revenue of Gentian Diagnostics? | Gentian Diagnostics's last 12-month revenue is $16.0M. |
| What is the current EBITDA of Gentian Diagnostics? | Gentian Diagnostics's last 12-month EBITDA is $2.6M. |
| What is the current EV/Revenue multiple of Gentian Diagnostics? | Current revenue multiple of Gentian Diagnostics is 4.0x. |
| What is the current EV/EBITDA multiple of Gentian Diagnostics? | Current EBITDA multiple of Gentian Diagnostics is 24.7x. |
| What is the current revenue growth of Gentian Diagnostics? | Gentian Diagnostics revenue growth between 2023 and 2024 was 12%. |
| Is Gentian Diagnostics profitable? | Yes, Gentian Diagnostics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
